Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial

References

• Kahrilas PJ. Gastroesophageal relfux disease. N Engl J Med. 2008;359(16):1700–1707. doi:10.1056/NEJMcp080468418923172
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Talley N. Gastro-esophageal reflux disease. Lancet. 2006;367(9528):2086–2100. doi:10.1016/S0140-6736(06)68932-016798392
   PubMed Web of Science ®Google Scholar
• Khan M, Santana J, Donnellan C. Medical treatment in the short term management of reflux esophagitis. Cochrane Database Syst Rev. 2007;2:CD003244.
   Google Scholar
• Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112(6):1798–1810.9178669
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Fennerty MB, Joelsson B. High- versus standard-dose ranitidine for control of heartburn in poorly response gastroesophgeal reflux disease: a prosptive, controlled trial. Am J Gastroenterol. 1999;94(1):92–97. doi:10.1111/j.1572-0241.1999.00777.x9934737
   PubMed Web of Science ®Google Scholar
• Donnellan C, Sharma N, Preston C. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. 2005;2:CD003245.
   Google Scholar
• Dent J, Talley NJ. Overview: initial and long-term management of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2003;17(Suppl 1):53–57. Review.
   PubMed Web of Science ®Google Scholar
• Laine L, Ahnen D, McClain C, et al. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2000;14(6):651–668. Review.10848649
   PubMed Web of Science ®Google Scholar
• Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–2953. doi:10.1001/jama.296.24.294717190895
   PubMed Web of Science ®Google Scholar
• Garcia Rodríguez LA, Ruigómez A. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk? Epidemiology. 1997;8(5):571–574.9270961
   PubMed Web of Science ®Google Scholar
• Dial S, Alrasadi K, Manonkian C, et al. Risk of Clostridium difficile among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. Cmaj. 2004;171(1):33–38.15238493
   PubMed Web of Science ®Google Scholar
• Gerson LB, Robbins AS, Garber A, et al. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol. 2000;95(2):395–407. doi:10.1111/j.1572-0241.2000.01759.x10685741
   PubMed Web of Science ®Google Scholar
• Vakil N. Review article: cost-effectiveness of different GERD management strategies. Aliment Pharmacol Ther. 2002;16(Suppl 4):79–82. Review.
   PubMed Web of Science ®Google Scholar
• Tytgat GN. Review article: management of mild and severe gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2003;17(Suppl 2):52–56. Review.12786613
   PubMed Web of Science ®Google Scholar
• Hsu PI, Lu CL, Wu DC, et al. Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis. Clin Gastroenterol Hepatol. 2015;13(5):859–866. doi:10.1016/j.cgh.2014.09.03325245625
   PubMed Web of Science ®Google Scholar
• Metz DC, Howden CW, Perez MC, et al. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther. 2009;29(7):742–754. doi:10.1111/j.1365-2036.2009.03954.x19210298
   PubMed Web of Science ®Google Scholar
• Sharma P, Shaheen NJ, Perez MC, et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation–results from two randomized controlled studies. Aliment Pharmacol Ther. 2009;29(7):731–741. doi:10.1111/j.1365-2036.2009.03933.x19183157
   PubMed Web of Science ®Google Scholar
• Richter JE, Kahrilas PJ, Johanson J, et al; Esomeprazole Study Investigators. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001;96(3):656–665. doi:10.1111/j.1572-0241.2001.3600_b.x11280530
   PubMed Web of Science ®Google Scholar
• Schmitt C, Lightdale CJ, Hwang C, et al. A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis. Dig Dis Sci. 2006;51(5):844–850. doi:10.1007/s10620-005-9062-416642422
   PubMed Web of Science ®Google Scholar
• Wong WM, Lai KC, Lam KF, et al. Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. Aliment Pharmacol Ther. 2003;18(6):595–604.12969086
   PubMed Web of Science ®Google Scholar
• Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45(2):172–180.10403727
   PubMed Web of Science ®Google Scholar
• Fock KM, Teo EK, Ang TL, et al. The utility of narrow band imaging in improving the endoscopic diagnosis of gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2009;7(1):54–59. doi:10.1016/j.cgh.2008.08.03018852068
   PubMed Web of Science ®Google Scholar
• Kasap E, Zeybel M, Aşık G, et al. Correlation among standard endoscopy, narrow band imaging, and histopathological findings in the diagnosis of nonerosive reflux disease. J Gastrointestin Liver Dis. 2011;20(2):127–130.21725507
   PubMed Web of Science ®Google Scholar
• Vakil N, van Zanten SV, Kahrilas P, et al; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–1920. doi:10.1111/j.1572-0241.2006.00630.x16928254
   PubMed Web of Science ®Google Scholar
• Hu WHC, Lam KF, Wong YH, et al. The Hong Kong index of dyspepsia: a validated symptom severity questionnaire for patients with dyspepsia. J Gastroenterol Hepatol. 2002;17(5):545–551.12084027
   PubMed Web of Science ®Google Scholar
• Revicki DA, Crawley JA, Zodet MW, et al. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1999;13(12):1621–1630.10594397
   PubMed Web of Science ®Google Scholar
• Remes-Troche JM, Sobrino-Cossio S, Soto-Perez JC, et al. Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study. Clin Drug Investig. 2014;34(2):83–93. doi:10.1007/s40261-013-0135-4
   PubMed Web of Science ®Google Scholar
• Tytgat G. Long-term GERD management: the individualized approach. Drugs Today (Barc). 2006;42(Suppl B):23–29. Review.16986068
   PubMed Web of Science ®Google Scholar
• Revicki DA, Zodet MW, Joshua-Gotlib S, et al. Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity. Health Qual Life Outcomes. 2003;29(1):73. doi:10.1186/1477-7525-1-73
   Google Scholar
• Kahrilas PJ, Falk GW, Johnson DA, et al; The Esomeprazole Study Investigators. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther. 2000;14(10):1249–1258.11012468
   PubMed Web of Science ®Google Scholar
• Gralnek IM, Dulai GS, Fennerty MB, et al. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006;4(12):1452–1458. doi:10.1016/j.cgh.2006.09.01317162239
   PubMed Web of Science ®Google Scholar
• Metz DC, Vakily M, Dixit T, et al. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther. 2009;29(9):928–937. doi:10.1111/j.1365-2036.2009.03984.x19298580
   PubMed Web of Science ®Google Scholar
• Wu MS, Tan SC, Xiong T. Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2013;38(2):190–201. doi:10.1111/apt.1234923718547
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Furuta T. Efficacy of esomeprazole in treating acid-related diseases in Japanese populations. Clin Exp Gastroenterol. 2012;5:49–59. doi:10.2147/CEG.S2392622649281
   PubMedGoogle Scholar
• Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol. 2001;96(1):27–34. doi:10.1111/j.1572-0241.2001.03443.x11197282
   PubMed Web of Science ®Google Scholar
• Howden CW, Larsen LM, Perez MC, et al. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief. Aliment Pharmacol Ther. 2009;30(9):895–907. doi:10.1111/j.1365-2036.2009.04119.x19681809
   PubMed Web of Science ®Google Scholar
• Liang CM, Kuo MT, Hsu PI, et al. First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treat-ment of grades A and B gastroesophageal reflux disease. World J Gastroenterol. 2017;23(47):8395–8404. doi:10.3748/wjg.v23.i47.839529307999
   PubMed Web of Science ®Google Scholar
• Smout AJPM; Gastro-oesophageal reflux disease. Pathogenesis and diagnosis In: Champion MC, Orr WC editors. Evolving Concepts in Gastrointestinal Motility. Oxford, England: Blackwell Science; 199646–63.
   Google Scholar
• Van Thiel DH, Gavaler JS, Stremple J. Lower esophageal sphincter pressure in women using sequential oral contraceptives. Gastroenterology. 1976;71(2):232–234.939383
   PubMed Web of Science ®Google Scholar
• Behm BW, Peura DA. Dexlansoprazole MR for the management of gastroesophageal reflux disease. Expert Rev Gastroenterol Hepatol. 2011;5(4):439–445. doi:10.1586/egh.11.3721780890
   PubMed Web of Science ®Google Scholar
• Kukulka M, Eisenberg C, Nudurupati S. Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg. Clin Exp Gastroenterol. 2011;4:213–220. doi:10.2147/CEG.S2406322016582
   PubMedGoogle Scholar
• Fass R, Inadomi J, Han C, et al. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. Clin Gastroenterol Hepatol. 2012;10(3):247–253. doi:10.1016/j.cgh.2011.11.02122155561
   PubMed Web of Science ®Google Scholar
• Suzuki H, Matsuzaki J, Okada S, et al. Validation of the GerdQ questionnaire for the management of gastro-oesophageal reflux disease in Japan. United European Gastroenterol J. 2013;1(3):175–183. doi:10.1177/2050640613485238
   PubMed Web of Science ®Google Scholar